Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Neuroblastoma
High-risk and relapsed disease: MYCN amplification, ALK mutations and anti-GD2 therapy.
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Indexed in Crossref
51 abstracts matching neuroblastoma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:52 UTC. This is a keyword search, not the complete abstract book.
- 2941
- 774Aligned ECM influences neuroblastoma cell plasticity via YAP-WT1 association.Vic Zamloot, Chandra Kaladhar Vemula, Antonios Chronopoulos, JinSeok Park
- 7515Uncovering transdifferentiation mechanisms underlying heterogeneity in neuroblastomaMichele Tomanelli, Jennifer Hoti, Ilaria Medici, Chaimae Sellak et al.
- 7871Onvansertib-mediated PLK1 inhibition reduces cell viability in neuroblastoma cellsAileen A. Yasukochi, Susanna Kim, Carla Sampaio, Peter E. Zage
- 6175Development of a human neuroblastoma organoid modelSimon Tusnady, Eva Bakos, Anna Lovrics, Katalin Monostory et al.
- 1165Vps34 inhibition enhances immunogenicity and immune-mediated killing in MYCN-amplified neuroblastomaElisabetta Bartolini, Teresa L. Ramos, Ruize Gao, Bassam Janji
- 698Novel reporter tool for visualization of neuroblastoma cell state.Samantha Turk, Melody Allensworth, Justina McEvoy, Marybeth Lupo et al.
- 5294Epigenetic modulation by DNMT-1 inhibitor induces cell death in SK-N-AS neuroblastoma cellsShyam Sundar Jaganathan, Umamaheswari Natarajan, Appu Rathinavelu
- 3503Somatic changes in Y chromosome copy number are associated with clinical and molecular features in neuroblastomaTeodoro Rivera-Wills, Preshita Dave, Esther Rheinbay
- 1929Stag2-cohesin mediates 3d genome dynamics to regulate MYCN driven oncogenic transcriptome in neuroblastoma.Jee-Youn Kang, Kaitlyn Tremble, Zhihui Liu, Carol J. Thiele
- 2650Breaking immune silence: Tumor-targeted molecular therapy reprograms the tumor-immune interface in progressive neuroblastomaLoganayaki Periyasamy, Sreenidhi Mohanvelu, Sheeja Aravindan, Poorvi Subramanian et al.
- 3355Exosomal genetic cargo shift dictated by RD3 deficiency steers progressive neuroblastoma evolutionAfsana Parveen Jahir Hussain, Sreenidhi Mohanvelu, Loganayaki Periyasamy, Poorvi Subramanian et al.
- 5690Mechanisms of efficacy of endonuclease FEN1 inhibition in neuroblastomaCarla S. Sampaio, Eric Wu, Madison Cinelli, Erica Steen et al.
- 5668USP7 and ITCH/UBE4B ubiquitin ligase regulate the switch between apoptosis and necroptosis via Ku70 and c-FLIPL polyubiquitination in neuroblastoma.Christophe Le Clorennec, Carla Sampaio, Peter E. Zage
- 3964Spatial profiling of the neuroblastoma tumor microenvironment using seqFISHChristopher Riccardi, Michal Polonsky, Michael J. Zobel, Rebekah Kennedy et al.
- 7875Eflornithine and venetoclax combination therapy: Targeting senescence to induce apoptosis in neuroblastomaTarlan Arjmandi, Jeremy Hengst, Muhammad Younis, Meenakshi Shukla et al.
- 3129Proteasome-associated DUB inhibition by VLX1570 targets UCHL5/USP14 and enhances cisplatin efficacy in neuroblastomaYi Ju Kao, Kuan-Lin Kuo, Chen-Hsun Hsu, Shih-Ming Liao et al.
- 5785RBM39 degrader anticancer activity against neuroblastoma: CDKN2A/B deletion as a biomarkerJames Finn, Imad salhab, Haihong Jin, Fei Liu et al.
- 5966Barcoded cell state specific transcription factors screen identifies SIX1 as a critical regulator of neuroblastoma plasticity and drug resistanceXingyu Liu, Ying Wu, Haiyan Lei, Wendy Fang et al.
- 178Exploring the role of catecholamine signaling in CD8+ T cell immunity to neuroblastoma.Mark B. Chudnovsky, Daniela Vega-Mendoza, Elinor L. DeCleene, Jose Almeida-Santos et al.
- 648PP2A reactivation upregulates FGA gene in neuroblastoma.Nazia Nazam, Shamza Manzoor, Maryam Ghufran, Morgan L. Brown et al.
- 5317Evaluation of circulating tumor DNA as a biomarker for early relapse detection and molecular profiling in patients with high-risk neuroblastoma.Natalia Wojciechowska, David Farbo, Tiffany Duque, Angela Brentlinger et al.
- 1154Multi-omic profiling of cellular heterogeneity and microenvironmental remodeling underlying treatment resistance in neuroblastomaEun Seop Seo, JI WON LEE, In Woo Hwang, Woong-Yang Park et al.
- 7066Comparative in vivo evaluation of RG-7388, CM-272, and SGI-1027 to determine epigenetic targeting as an effective strategy for treating high-risk neuroblastoma.Umamaheswari Natarajan, Shyam S. Jaganathan, Appu Rathinavelu
- 5888Quantitative phospho-proteomics uncovers CX-4945 effects on translational control and differentiation in neuroblastomaMarudhu Pandiyan Shanmugam, Muhammed Danial, Upendarrao Golla, Rifat Tasnim Juthi et al.
- CT272Clinical trial in progress: BCC022 a phase II trial of tipifarnib and naxitamab for relapsed/refractory neuroblastomaValerie Brown, Hong-Gang Wang, Genevieve Bergendahl, Arthur Berg et al.
- 1782Exome-scale CRISPR screening reveals master controllers of cell state maintenance in high-risk neuroblastomaGrace McKay-Corkum, Stephanie Nance, Noha AM Shendy, Shilpa Narina et al.
- 4603Favorable DMPK properties enable development of a novel arylsulfonamide RBM39 molecular glue degrader, PPI-101, for the treatment of neuroblastomaJian Wu, Lei Zhou, Yongzhi Gao, Shanshan Wang et al.
- 5299Epigenetic modulation by MDM2 and DNMT inhibitor promotes cell cycle arrest and programmed cell death in neuroblastoma cellsSruthika Talanki, Helen Le, Aashi Chhabra, Rhea Hede et al.
- 7801Preclinical efficacy of DLL3 targeted CAR T cells in neuroblastomaSalvatore M. Aspromonte, Tamar Feinberg, Ali Cihan, Samantha Brosius et al.
- 2133Fibronectin extra-domain B-recognizing gold nanoparticles as an innovative tool for neuroblastoma targeting.Chiara Barisione, Silvia Ortona, Veronica Bensa, Caterina Ivaldo et al.
- LB494Neuroblastoma phenotypic switching is blocked by FHD-286, a small molecule inhibitor of the SWI/SNF ATPases SMARCA2/4Carly M. Sayers, Wendy Z. Fang, Jenna M. Lacy, Stefano Di Giulio et al.
- 6169Evaluating TCR mimetic CAR T cell preclinical therapeutics in an immunocompetent MYCN-driven murine neuroblastoma allograft modelElisabeth Posthill, Minu Samanta, David Groff, Colleen Casey et al.
- 7814Ganglioside targeting: Exerting sweet revenge on neuroblastomaGuillermo Nicolas Dalton, Wonju Kim, Kevin H. Lu, Alessandro Gasparetto et al.
- LB492Chromosome 17q genes BIRC5, CDC6, IGF2BP1, and TK1 are oncogenic dependencies in MYCN-amplified neuroblastomaWanqi Fang, Bo Cheng, Steven J. Pastor, Michael J. Zobel et al.
- 2520Clinical impact of the personalized medicine for neuroblastoma patients: Six years of experience of the PREME programFrancesca Parisi, Eleonora Ciampi, Veronica Bensa, Federica Serafino et al.
- 4732Anaplastic lymphoma kinase harnesses the SLC4A7 bicarbonate transporter to intensify de novo nucleotide synthesis in neuroblastoma and lung cancerRuth Palmer, Wei-Yun Lai, Tzu-Po Chuang, Joel Johansson et al.
- 4027Co-targeting GPC2 and B7-H3 with CAR T cells achieves durable responses in preclinical high-risk neuroblastoma and medulloblastoma modelsPatrick M. Schürch, Benjamin Draper, Vincent P. Zecchino, Hehai Pan et al.
- 7810Engineering macrophages as a novel therapeutic approach for high-risk neuroblastomaKe-En Tan, Kok Siong Yeo, Cheng Zhang, Caleb Baker et al.
- LB016Sensitive detection of MYCN amplified neuroblastoma in blood samples with structural variants using standard whole genome sequencingPandurang Kolekar, Rebecca S. Kaufman, Hanxia Li, Yanling Liu et al.
- 4026Spatial T-cell receptor profiling uncovers barriers to T-cell engagement and shared tumor-reactive clonotypes in high-risk neuroblastomaYiyue (January) Jiang, Wenbao Yu, Stephanie Pedersen, Jenna Eagles et al.
- 3707Durable remission of high-risk and refractory neuroblastoma by PHOX2B derived peptide-HLA directed CAR T cells: An IND enabling studyMuzamil Y. Want, Richa Kapoor, David Groff, Keelan O’Reilly et al.
- 639Distinct microenvironments define subtypes of neuroblastoma.Joseph Seamus Toker, Katherine Elizabeth Masih, Noemi Kedei, Zahin Islam et al.
- 7879Opaganib in combination with oxaliplatin and doxorubicin as a novel salvage therapy for relapsed/refractory high-risk neuroblastomaJeremy Hengst, Mohammad Haque, Muhammad Younis, Thussenthan Walter Angelo et al.
- CT270Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomasGiselle Saulnier Sholler, Genevieve Bergendahl, Kevin Bielamowicz, Derek Hanson et al.
- 2995ATRX in-frame fusions promote endogenous chemoresistance programs but yield immunotherapeutic vulnerabilities in neuroblastomaMohammad Ali Mohammad Nezhady, Sheetal Bhatara, Siarhei Hladyshau, Estevez Prado Daniel et al.
- 5617Humanized antibody Fab-TCR T cells targeting GPC2 effectively regress neuroblastoma via enhanced TCR signaling and sustained cytotoxicityMingyu Huo, Alex Quan, Dan Li, Laura E. Hutchins et al.
- 4025Sequential cell free DNA analysis reveals genetic heterogeneity in patients with relapsed neuroblastoma enrolled in the SIOPEN-ITCC BEACON studyYasmine Iddir, Charles Bobin, Alexandra Saint-Charles, Julien Masliah-Planchon et al.
- 1469Multi-omics profiling of neuroblastoma identifies immunological biomarkers associated with higher risk of relapse: Results from the MICCHADO study.Antonio Colaprico, Alexandra Saint-Charles, Stelly Ballet, Charles Bobin et al.
- 7805Development of a GFRA2-targeting antibody drug conjugate for neuroblastoma (NB), and Ewing sarcoma (EWS)Amber K. Hamilton, Seungmin Shin, Raphael D. Lopez, Nicholas Hartnett et al.
- 4568Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular viability, affects energy metabolism, induces DNA damage, and drives tumor regression in preclinical models of neuroblastomaAmy Yu, Sophia Varriano, Victor J. Collins, Ariana E. Nelson et al.